ASD/PFO devices: what is in the pipeline?
Since the initial description of an atrial septal defect (ASD) occluding device in the mid-1970s by King and Mills, a number of devices have been developed. To date, various transcatheter devices and methods to close congenital heart defects are currently available commercially or within clinical trials. Devices have been designed specifically for the ASD and patent foramen ovale (PFO). The trend in interventional treatment of intracardiac shunts is toward defect-specific systems and new devices minimizing the foreign material left in the atria. This review first focuses on new devices that are not approved in the United States but are elsewhere, and then reviews the experimental devices for PFO and ASD closure.
Majunke
Nicolas
N
CardioVascular Center Frankfurt, Frankfurt, Germany.
Sievert
Horst
H
D006328:Cardiac Catheterization; D054092:Foramen Ovale, Patent / Q000601:surgery*; D006801:Humans; D019736:Prostheses and Implants / Q000639:trends*; D011474:Prosthesis Design / Q000639:trends*; D019919:Prosthesis Implantation